The first clinical experience with 68Ga-CPCR4-2 (prepared in the radiopharmacy of our hospital) PET/CT imaging was very encouraging and demonstrated the clinical applicability and feasibility of using that molecular imaging technique for confirming CXCR4 expression in patients with SCLC; this information can then be used to select patients with high CXCR4 expression for radiopeptide therapy according to the theranostics principle (Figure 6). Here, CXCR4 is linked to small cell lung carcinoma.